More gain, less pain: Spinifex raises funds to target angiotensin II type 2 receptors
This article was originally published in Scrip
Executive Summary
Spinifex Pharmaceuticals, a small Australian biotech company with a clinical asset focused on treating neuropathic pain, has raised an extension of its series B round. Existing investors GBS Venture Partners, Brandon Capital Partners, Uniseed Management and UniQuest have put in a further A$6.25 million, bringing the series B total to A$18.25 million (around $19 million) and the amount raised to date by the firm to A$22.5 million.